Fish oil pill flunks atrial fibrillation study

Omega-3 fatty acids have become a popular supplement taken by millions of people anxious to avoid heart disease. But the FDA says that a prescription strength version of the fish oil supplement failed to help patients with atrial fibrillation in a large study. A total of 663 patients suffering from erratic heart beats were split into two groups and given either the prescription treatment Lovaza or a placebo over a six month period. The drug was well tolerated but failed to register on the efficacy side of the equation. Report

Suggested Articles

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.

Chief Operating Officer Dan Paterson will lead the company while it looks for a permanent successor with commercial chops.